Peroxisome proliferator-activated receptor ligands in atherosclerosis

Juan F. Viles-Gonzalez, Brian G. Choi, Valentin Fuster, Juan J. Badimon

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.

Original languageEnglish (US)
Pages (from-to)1393-1403
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number11
StatePublished - Nov 1 2004


  • Atherosclerosis
  • Coronary artery disease
  • Fibrate
  • PPAR
  • Thiazolidinedione

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Peroxisome proliferator-activated receptor ligands in atherosclerosis'. Together they form a unique fingerprint.

Cite this